Association between mutant IDHs and tumorigenesis in gliomas. (Q55457331)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29633022 AND SRC:MED&resulttype=core&format=json

22 March 2020

title

Association between mutant IDHs and tumorigenesis in gliomas (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29633022 AND SRC:MED&resulttype=core&format=json

22 March 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29633022 AND SRC:MED&resulttype=core&format=json

22 March 2020

author name string

Yuichi Hirose

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29633022 AND SRC:MED&resulttype=core&format=json

22 March 2020

publication date

9 April 2018

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29633022 AND SRC:MED&resulttype=core&format=json

Medical Molecular Morphology

22 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29633022 AND SRC:MED&resulttype=core&format=json

22 March 2020

volume

51

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29633022 AND SRC:MED&resulttype=core&format=json

22 March 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29633022 AND SRC:MED&resulttype=core&format=json

22 March 2020

page(s)

194-198

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29633022 AND SRC:MED&resulttype=core&format=json

Direct activation of TERT transcription by c-MYC.

22 March 2020

cites work

1 reference

12 December 2020

Formation of intracranial tumors by genetically modified human astrocytes defines four pathways critical in the development of human anaplastic astrocytoma

1 reference

12 December 2020

A P53-dependent, telomere-independent proliferative life span barrier in human astrocytes consistent with the molecular genetics of glioma development.

1 reference

12 December 2020

Telomerase and cancer therapeutics

1 reference

12 December 2020

An integrated genomic analysis of human glioblastoma multiforme

1 reference

12 December 2020

IDH1 and IDH2 mutations in gliomas

1 reference

12 December 2020

Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha

1 reference

12 December 2020

Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

1 reference

12 December 2020

Alternative lengthening of telomeres: models, mechanisms and implications

1 reference

12 December 2020

Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases

1 reference

12 December 2020

Inhibition of 2-oxoglutarate dependent oxygenases

1 reference

12 December 2020

Identification of additional IDH mutations associated with oncometabolite R(-)-2-hydroxyglutarate production

1 reference

12 December 2020

Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation.

1 reference

12 December 2020

IDH mutation impairs histone demethylation and results in a block to cell differentiation

1 reference

12 December 2020

IDH1 and IDH2 mutations in tumorigenesis: mechanistic insights and clinical perspectives

1 reference

12 December 2020

Whole-exome sequencing identifies ATRX mutation as a key molecular determinant in lower-grade glioma

1 reference

12 December 2020

TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal

1 reference

12 December 2020

2-hydroxyglutarate as a magnetic resonance biomarker for glioma subtyping

1 reference

12 December 2020

An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells.

1 reference

12 December 2020

Methylation of the TERT promoter and risk stratification of childhood brain tumours: an integrative genomic and molecular study.

1 reference

12 December 2020

IDH1/2 mutations target a key hallmark of cancer by deregulating cellular metabolism in glioma

1 reference

12 December 2020

Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML.

1 reference

12 December 2020

Cancer-associated IDH2 mutants drive an acute myeloid leukemia that is susceptible to Brd4 inhibition

1 reference

12 December 2020

IDH1/2 mutation detection in gliomas

1 reference

12 December 2020

Mutant IDH1-driven cellular transformation increases RAD51-mediated homologous recombination and temozolomide resistance

1 reference

12 December 2020

Diffusely infiltrating astrocytomas: pathology, molecular mechanisms and markers

1 reference

12 December 2020

Cancer. The transcription factor GABP selectively binds and activates the mutant TERT promoter in cancer.

1 reference

12 December 2020

Noninvasive Quantification of 2-Hydroxyglutarate in Human Gliomas with IDH1 and IDH2 Mutations.

1 reference

12 December 2020

Extreme Vulnerability of IDH1 Mutant Cancers to NAD Depletion.

1 reference

12 December 2020

Biological Significance of Mutant Isocitrate Dehydrogenase 1 and 2 in Gliomagenesis

1 reference

12 December 2020

IDH mutations in cancer and progress toward development of targeted therapeutics

1 reference

12 December 2020

Rapid Conversion of Mutant IDH1 from Driver to Passenger in a Model of Human Gliomagenesis

1 reference

12 December 2020

IDH1 and IDH2 mutations as novel therapeutic targets: current perspectives

1 reference

12 December 2020

The Role of ATRX in the Alternative Lengthening of Telomeres (ALT) Phenotype

1 reference

12 December 2020

Mutant IDH1 Expression Drives TERT Promoter Reactivation as Part of the Cellular Transformation Process

1 reference

12 December 2020

Telomeres in cancer: tumour suppression and genome instability

1 reference

12 December 2020

Pan-mutant IDH1 inhibitor BAY 1436032 for effective treatment of IDH1 mutant astrocytoma in vivo

1 reference

12 December 2020

Solving the Telomere Replication Problem.

1 reference

12 December 2020

Mutant IDH1 cooperates with ATRX loss to drive the alternative lengthening of telomere (ALT) phenotype in glioma.

1 reference

12 December 2020